Savvy Psychopharmacology

Paliperidone palmitate: Adjusting dosing intervals and measuring serum concentrations

Author and Disclosure Information

 

References

Would monitoring a patient’s paliperidone serum concentrations be useful? Currently, measuring an individual’s paliperidone serum concentration is generally considered unwarranted.3,4 One of the major reasons is a lack of appropriately designed studies to determine a therapeutic range.5 Flexible dose designs, commonly used in registration studies, cloud the relationships between concentration, time, response, and adverse effects. There are additional problems that are the result of diagnostic heterogeneity and placebo responders. A well-designed study to determine the therapeutic range would have ≥1 fixed dose groups and be diagnostically homogeneous. There are currently only a limited number of clinical laboratories that have implemented suitable assays.

Given the lack of knowledge of a therapeutic range, assured knowledge of nonadherence to LAIs, and the absence of significant drug interactions for paliperidone, there remain a few reasonable justifications for obtaining a patient’s paliperidone serum concentration (Table). If the patient had a good response with mild adverse effects, there is no reason to obtain a paliperidone serum concentration or make any change in the medication or dose. However, if the patient had a good response accompanied by moderate or severe adverse effects, or the patient has a poor response, then obtaining the paliperidone serum concentration could help determine an appropriate course of action.

Using paliperidone serum concentrations to guide treatment

CASE CONTINUED

After the second dose at the increased frequency on Day 252, the paliperidone serum concentration was maintained above 40 ng/mL. Mr. B continued to tolerate the LAI well and no longer reported any breakthrough hallucinations.

Related Resources

Drug Brand Names

Paliperidone palmitate • Invega Sustenna
Risperidone • Risperdal

Pages

Recommended Reading

Catatonia: How to identify and treat it
MDedge Psychiatry
Bugs on her skin—but nobody else sees them
MDedge Psychiatry
FAST and RAPID: Acronyms to prevent brain damage in stroke and psychosis
MDedge Psychiatry
Clozapine-induced GI hypomotility: From constipation to bowel obstruction
MDedge Psychiatry
FDA approves Perseris for schizophrenia
MDedge Psychiatry
Peer-comparison letters reduce physician quetiapine prescribing
MDedge Psychiatry
Prescribing psychotropics to pediatric patients
MDedge Psychiatry
Judge seeks replication of efforts to support people with SMI
MDedge Psychiatry
For people with SMI, disclosure still challenging
MDedge Psychiatry
Address physical health risks of people with SMI
MDedge Psychiatry